Dirk Brockstedt

Company: Rapt Therapeutics

Job title: CSO

Seminars:

Developing a Highly Potent & Selective CCR4 Small Molecule Antagonist FLX475 to Target Treg Selectively in the TME 12:30 pm

Discussing current challenges to effectively target regulatory T cells in the TME Deploying a computational biology and large dataset approach to drug development and patient selection strategies Review of clinical status of FLX475Read more

day: Day Two | Track B | Afternoon